Whole‐genome sequencing analysis of breast cancer samples can identify tumors that exhibit genomic rearrangements due to functional deficiencies in homologous recombination even BRCA wild‐type cells, and these characteristics can be used to predict therapy response to PARP inhibitors. This evidence concerns the gene PARP1 and breast cancer.